Related content

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

By Soeda Hiroshi   Shimodaira Hideki   Watanabe Mika   Suzuki Takao   Gamoh Makio   Mori Takahiro   Komine Keigo   Iwama Noriyuki   Kato Shunsuke   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 670-677

Springer Publishing Company

Access to resources Recommend Favorite

Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy

By          

Oncology Letters, Vol. 4, Iss. 5, 2012-01 ,pp. : 905-909

Spandidos Publications

Access to resources Recommend Favorite

Oxaliplatin for colorectal cancer: recent evidence from clinical trials

By Stein Alexander   Quidde Julia   Arnold Dirk  

Colorectal Cancer, Vol. 2, Iss. 2, 2013-04 ,pp. : 135-144

Future Medicine

Access to resources Recommend Favorite

Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer

By Sørbye Halfdan   Dahl Olav  

Acta Oncologica, Vol. 43, Iss. 5, 2004-07 ,pp. : 495-498

Informa Healthcare

Access to resources Recommend Favorite